Investigating how to overcome treatment resistance in a specific type of brain tumor using a new drug.
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma
This study is looking at how a drug called ONC201 can help children and young adults with a tough brain tumor called diffuse midline glioma, especially those with a specific mutation, and aims to find ways to make the treatment work better for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11016954 on NIH RePORTER |
What this research studies
This research focuses on children and young adults with diffuse midline glioma (DMG) that have the H3K27M mutation, a condition that currently has no effective treatments beyond radiation. The study aims to understand how the drug ONC201 works in these tumors and to identify ways to enhance its effectiveness, especially in cases where tumors show resistance. By analyzing tumor samples and patient data, researchers hope to determine which patients are most likely to benefit from ONC201 and develop combination therapies that could improve outcomes. The research involves both laboratory studies and clinical data analysis to inform treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with H3K27M-mutant diffuse midline glioma.
Not a fit: Patients with other types of brain tumors or those without the H3K27M mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and survival rates for patients with H3K27M-mutant diffuse midline glioma.
How similar studies have performed: Other research has shown promising results with ONC201 in similar tumor types, indicating potential for success in this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Koschmann, Carl J — University of Michigan at Ann Arbor
- Study coordinator: Koschmann, Carl J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.